Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Biomaterials Advances is Scopus-indexed (Q1, CiteScore 13.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 2772-9508Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: About US$3,750 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biomedical Engineering | 32 / 342 | 90th | Q1 |
| Bioengineering | 20 / 168 | 88th | Q1 |
| Biomaterials | 19 / 146 | 87th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q1, CiteScore 13.6.
Biomaterials Advances is Q1 in Biomedical Engineering (rank 32 of 342), Q1 in Bioengineering (rank 20 of 168) and Q1 in Biomaterials (rank 19 of 146), by CiteScore 2025.
Biomaterials Advances is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 13.6, which places it in quartile Q1 at the 90th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.138, quartile Q1, with an H-index of 212.
The publisher lists an article processing charge of about US$3,750 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Biomaterials Advances is published by Elsevier Ltd. Its ISSN is 2772-9508.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Biomaterials Advances has an h-index of 57 and a 2-year mean of 5.32 citations per paper (OpenAlex). Its Scopus CiteScore is 13.6, quartile Q1. On 2-year citations it ranks #71 of 322 Scopus journals in Biomedical Engineering.
Biomaterials Advances published 435 papers in 2025; its busiest recent year was 2022 with 518. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2026), authors are most often from China (51.6%), United States (9%) and Japan (4.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (1.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.